MIF and Alzheimer disease: Our further evaluation of the inhibitory effects of the individual components of bufadienolides on the MIF pathway revealed that the inhibitory effects were significantly stronger for resibufogenin and cinobufagin than for the other components (Figure 3B), highlighting the therapeutic potential of these two compounds as treatments for AD.